DiaMedica Therapeutics (DMAC) Net Cash Flow (2018 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Net Cash Flow of -$10.8 million for Q1 2026, down 2372.25% year-over-year from $474376.1 in Q1 2025, and down 187.46% quarter-over-quarter from $12.3 million in Q4 2025.
DiaMedica Therapeutics (DMAC) Net Cash Flow (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at -$10.8 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 2372.25% year-over-year to -$10.8 million; the TTM figure through Mar 2026 stood at $2.3 million (up 363.21% YoY), while the FY2025 annual figure was $12.6 million, up 931.49% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$10.8 million, down from $12.3 million in the prior quarter.
- The five-year high for Net Cash Flow was $12.3 million in Q4 2025, with the low at -$10.8 million in Q1 2026.
- The 5-year median for Net Cash Flow is -$436000.0 (2025), against an average of $9470.6.
- The sharpest annual moves came in 2023 and 2026: Net Cash Flow soared 12206.67% in 2023, then slumped 2372.25% in 2026.
- DiaMedica Therapeutics' Net Cash Flow stood at $2.0 million in 2022, then advanced by 18.09% to $2.3 million in 2023, then sank by 147.99% to -$1.1 million in 2024, then jumped by 1211.27% to $12.3 million in 2025, then sank by 187.46% to -$10.8 million in 2026.
- Business Quant data shows DMAC's Net Cash Flow at -$10.8 million in Q1 2026, $12.3 million in Q4 2025, and -$786000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | 275,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 275,000.00 |
| Jun 30, 2026 | 275,000.00 |
| Mar 31, 2026 | -10.78 Mn |
| Mar 31, 2026 | -10.78 Mn |
| Dec 31, 2025 | 12.32 Mn |
| Dec 31, 2025 | 12.32 Mn |
| Sep 30, 2025 | -786,000.00 |
| Sep 30, 2025 | -786,000.00 |
| Jun 30, 2025 | 1.52 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Mar 31, 2025 | -436,000.00 |
| Mar 31, 2025 | -436,000.00 |
| Dec 31, 2024 | -1.11 Mn |
| Dec 31, 2024 | -1.11 Mn |
| Sep 30, 2024 | -9.93 Mn |
| Sep 30, 2024 | -9.93 Mn |
| Jun 30, 2024 | 11.97 Mn |
| Jun 30, 2024 | 11.97 Mn |
| Mar 31, 2024 | -2.45 Mn |
| Mar 31, 2024 | -2.45 Mn |